iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer...
COVID-19
Quipt Home Medical Announces Normal Course Issuer Bid
CINCINNATI, May 02, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June...
MedMira Announces the Hire of Vice President of Business Development
HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion...
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum...
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused...
Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness...
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting
Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025WOODCLIFF LAKE, N.J., April 30,...
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel...
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting...
Entourage Health Reports Fiscal Year 2023 Financial Results and Posts $54 Million in Total Revenues
Strategic Cost Management Signals Stronger Financial Health and Future StabilityGross profit before fair value changes reached $2.4 million, reflecting a...
HD Nursing Honored as Silver Stevie® Award Winner in 2024 American Business Awards®
BENTON, Ark.--(BUSINESS WIRE)--HD Nursing, the leading patient safety solution that combines predictive analytics with individualized fall and pressure injury prevention,...
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Next safety cohort to begin escalated dosing soonOCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for...
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim,...
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage...
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
- Top-line Results Expected in the Second Half of 2024 -PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics,...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in...
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the...